Led by OINDP experts from Next Breath and Nanopharm, both Aptar Pharma companies, this webinar will examine the analytical methods and regulatory frameworks associated with ensuring and establishing bioequivalence. It will question which analytical methods are most relevant to OINDP in vitro bioequivalence studies, as well as explore what supporting evidence can be generated to aid formulation optimization, therefore helping to expedite successful product development and regulatory submission.
This webinar, which is sponsored by Malvern Panalytical and is free to attend, will be co-presented by Dr. Julie D. Suman, Founder & President, Next Breath and Dr. Jag Shur, CEO, Nanopharm.
The webinar will be available on-demand after the live presentation.
